CLINICAL_TRIALS
trial_result
· 2025-06-29
Clinical Trial Update: Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome [Phase 2]
Summary
Phase 2 trial evaluating the safety and tolerability of CFZ533 in Sjögren's syndrome has completed. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Sjogren's Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-06-29